Neurogene

NGNE

Current ValuationThe current P/E ratio is -4.96, within the reasonable range, cheaper than 66.67% of the time in the past 1 years, and the industry ranks 384/608, the industry Median -1.97.

-4.96xP/E
Stock price$27.55Earnings per share$-5.55

Historical Valuation

P/E ratioTypical rangeMedian

Peer P/E ratio Comparison

It displays how the company's P/E ratio compares to top companies within its industry.
013263952

The industry median valuation is currently at or below 0 and may not serve as a meaningful benchmark.

Industry P/E ratio Comparison

This shows the distribution of companies by P/E ratio range and their projected earnings per share growth for the next fiscal year.
0x30x60x90x120x150x
P/E ratio
Name/Symbol
GILDUSGilead Sciences
-54.80x151.28%$211.64B
MRNAUSModerna
-28.09x17.02%$88.52B
CSLLYUSCSL Limited
-26.29x--$67.79B
NTRAUSNatera
-310.48x5.57%$59.72B
RVMDUSRevolution Medicines
-23.19x61.94%$41.00B
ROIVUSRoivant Sciences
-100.13x146.69%$26.66B
INSMUSInsmed
-40.60x72.84%$24.59B
BNTXUSBioNTech SE
-11.33x18.75%$22.15B
BBIOUSBridgebio Pharma
-24.75x28.03%$14.65B
SMMTUSSummit Therapeutics
-14.94x20.06%$12.79B
KYMRUSKymera Therapeutics
-30.13x8.57%$10.53B
TWSTUSTwist Bioscience
-73.57x28.63%$10.06B
MDGLUSMadrigal Pharma
-30.59x51.30%$9.94B
PCVXUSVaxcyte
-9.17x47.91%$9.76B
IBRXUSImmunityBio
-8.85x151.32%$8.79B
CYTKUSCytokinetics
-9.80x6.85%$8.76B
SYREUSSpyre Therapeutics
-56.68x45.60%$8.51B
ARWRUSArrowHead Pharma
-26.44x35,923.70%$8.46B
PRAXUSPraxis Precision Medicines
-23.54x3.71%$7.98B
ABVXUSAbivax SA
-16.23x22.99%$7.55B

Risk Warning

Timeframes using financial data from S&P Global. The feature provides key metrics such as price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S) ratios, and dividend yield. For reference only and does not constitute investment advice.